收藏切换
A comparative analysis of stem cell therapy regulatory models worldwide
收藏切换
Zhao LIU1, Yang ZHENG1, Jun FANG1, *, Lin YUAN2, *
Chinese Journal of New Drugs | 2026, 35(18) : 1925 - 1931
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(18): 1925-1931
A comparative analysis of stem cell therapy regulatory models worldwide
Full
Zhao LIU1, Yang ZHENG1, Jun FANG1, *, Lin YUAN2, *
Affiliations
  • 1Institute of Executive Development, National Medical Products Administration, Beijing 100073, China
  • 2China Society for Drug Regulation, Beijing 100050, China
Published: 2026-09-30 doi: 10.20251/j.cnki.1003-3734.2026.18.003
Outline
收藏切换

With the rapid advancement of stem cell therapy, its application in clinical medicine has expanded significantly, posing new challenges to existing regulatory frameworks. This article systematically reviews the regulatory models for stem cell therapy across multiple countries, and based on a comparative analysis of regulatory policies, technical guidelines, and peer-reviewed literature, summarizes the major approaches and common trends regarding risk stratification, access pathways, and lifecycle quality management. The analysis highlights the widespread adoption of risk-based classification and accelerated access mechanisms to balance efficacy and safety. Through comparative analysis, the article details the evolution of China's regulatory system for stem cell therapy, emphasizing the characteristics of the "dual-track" model-parallel management through drug-based regulation and clinical research filing. In response to current issues such as unclear classification, fragmented oversight, and insufficient international alignment, the article proposes five key strategies: establishing scientific classification standards, improving quality control systems, facilitating clinical translation, strengthening ethical oversight and information transparency, and deepening international cooperation. These recommendations aim to support the development of a scientific, standardized, and efficient regulatory framework with Chinese characteristics, while also offering insights for global regulatory practices.

stem cell therapy  /  regulatory system  /  risk-based classification  /  dual-track model  /  international comparison
刘钊, 郑杨, 房军, 袁林. 干细胞治疗监管模式的国际比较. 中国新药杂志, 2026 , 35 (18) : 1925 -1931 . DOI: 10.20251/j.cnki.1003-3734.2026.18.003
Zhao LIU, Yang ZHENG, Jun FANG, Lin YUAN. A comparative analysis of stem cell therapy regulatory models worldwide[J]. Chinese Journal of New Drugs, 2026 , 35 (18) : 1925 -1931 . DOI: 10.20251/j.cnki.1003-3734.2026.18.003
Year 2026 volume 35 Issue 18
60
7
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.18.003
  • Online Date:2026-10-26
  • Published:2026-09-30
Article Data
Affiliations
History
  • Accepted:2025-12-21
Affiliations
    1Institute of Executive Development, National Medical Products Administration, Beijing 100073, China
    2China Society for Drug Regulation, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.18.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT